ASH 2017 | Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status

Nirali Shah

CAR T-cell therapy development is progressing across a wide range of hematological malignancies, with the results highly anticipated in acute lymphoblastic leukemia (ALL) following the exciting results seen in lymphoma. In this interview, Nirali Shah, MD, of the National Cancer Institute, National Institutes of Health, Bethesda, MD, provides us with an update from the ALL group of on the ongoing Phase I clinical trial of anti-CD22 CAR T-cells for B-cell malignancies (NCT02315612). This agent is particularly exciting, as it is the first CAR T-cell product that is active in ALL which does not target CD19. Dr Shah touches upon whether the study cohort had received prior anti-CD19 or blinatumomab therapy, as well as their CD19 positivity status. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

Share this video